Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
暂无分享,去创建一个
M. Dimopoulos | J. San Miguel | S. Jagannath | S. Lonial | N. Munshi | P. Richardson | R. Kyle | S. Rajkumar | R. Orlowski | H. Avet-Loiseau | O. Sezer | J. S. San Miguel | H. Ludwig | D. Vesole | T. Facon | J. Zonder | J. Harousseau | B. Durie | J. Bladé | A. Palumbo | D. Siegel | K. Anderson | Kenneth Anderson | Nikhil C. Munshi
[1] A. Dispenzieri,et al. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. , 2008, Blood.
[2] R A Kyle,et al. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma , 2009, Leukemia.
[3] D. Esseltine,et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma , 2008, British journal of haematology.
[4] Bin Jiang,et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.
[5] B. Durie,et al. Eliminating the complete response penalty from myeloma response criteria. , 2008, Blood.
[6] S. Lonial,et al. Eliminating the complete response penalty from myeloma response assessment. , 2008, Blood.
[7] P. Richardson,et al. Clinically relevant end points and new drug approvals for myeloma , 2008, Leukemia.
[8] B. Durie,et al. Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide by H Prince, Brad Schenkel and Linda Mileshkin , 2007, Leukemia.
[9] L. Mileshkin,et al. Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide , 2007, Leukemia.
[10] M. Minden,et al. A phase II study of temozolomide therapy for poor-risk patients aged ⩾60 years with acute myeloid leukemia: low levels of MGMT predict for response , 2007, Leukemia.
[11] D. Esseltine,et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. , 2006, Blood.
[12] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[13] B. Durie. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. , 2006, European journal of cancer.
[14] M. Gordon. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma , 2006 .
[15] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[16] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[17] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[18] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.